Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment. The authors of this Review provide an overview of the complexity ...

The Small Cell Lung Cancer market growth is driven by factors like increase in the prevalence of Small Cell Lung Cancer, investments in research and development, entry of emerging therapies during ...

A new study published in the Annals of Surgical Oncology revealed that individuals with little muscle mass, segmentectomy ...

Zai Lab Limited ( NASDAQ: ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.